Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crisaborole - Pfizer

Drug Profile

Crisaborole - Pfizer

Alternative Names: AN-2728; Crisaborole ointment; Eucrisa; PF-06930164; PF-06940799; STAQUIS

Latest Information Update: 30 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anacor Pharmaceuticals
  • Developer Anacor Pharmaceuticals; Duke University; Pfizer Canada
  • Class Anti-inflammatories; Antipsoriatics; Heterocyclic bicyclo compounds; Nitriles; Nonsteroidal anti-inflammatories; Organic boron compounds; Phenyl ethers; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atopic dermatitis
  • Phase II Circumscribed scleroderma
  • Suspended Psoriasis

Most Recent Events

  • 16 Sep 2019 Pfizer plans a phase II trial for Dermatitis (Topical) in October 2019 (NCT04091087)
  • 31 Jul 2019 Pfizer plans a phase III trial for Atopic dermatitis (In children, In adults) (Topical, Ointment) in September 2019 (NCT04040192)
  • 01 Jul 2019 Registered for Atopic dermatitis (In adolescents, In adults, In children, In the elderly) in Israel (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top